Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA

被引:20
作者
Giraud, A
Ataman-Önal, Y
Battail, N
Piga, N
Brand, D
Mandrand, B
Verrier, B
机构
[1] Ecole Normale Super Lyon, CNRS, UMR103, Unite Mixte BioMerieux,Lab Retrovirol, F-69364 Lyon 07, France
[2] BioMerieux, Dept R&D, Marcy Letoile, France
[3] Univ Tours, CNRS, EP 117, Virol Lab, Tours, France
关键词
monoclonal antibody; immunization; human immunodeficiency virus type 1; envelope glycoprotein; Semliki Forest virus vector; naked RNA;
D O I
10.1016/S0166-0934(99)00009-9
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The Semliki Forest virus (SFV) vector system is a new approach for in vivo expression of heterologous proteins and can also be used to generate specific immune responses in animal models. HIV-1 envelope glycoprotein produced using the SFV expression system is correctly folded, cleaved, transported to the cell surface and exhibits functional activity. We evaluated a recombinant Semliki Forest virus naked RNA-based immunization protocol for generation of monoclonal antibodies against the HIV-I envelope glycoprotein. In vitro-transcribed RNA encoding for the SFV replicase complex and Env protein of HIV-1 (HXB2 strain) was injected intramuscularly to mice. This approach elicited an Env-specific antibody response in four mice out of five and a monoclonal antibody, 12H2, directed against gp41 was produced. Our results show that recombinant SFV RNA immunization can potentially be used as a quick and direct method to produce monoclonal antibodies, with the particular advantage that vectored RNA, rather than purified antigen, delivers a complex oligomer produced correctly. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:75 / 84
页数:10
相关论文
共 31 条
[1]  
André S, 1998, J VIROL, V72, P1497
[2]   SEMLIKI FOREST VIRUS EXPRESSION SYSTEM - PRODUCTION OF CONDITIONALLY INFECTIOUS RECOMBINANT PARTICLES [J].
BERGLUND, P ;
SJOBERG, M ;
GAROFF, H ;
ATKINS, GJ ;
SHEAHAN, BJ ;
LILJESTROM, P .
BIO-TECHNOLOGY, 1993, 11 (08) :916-920
[3]   DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees [J].
Boyer, JD ;
Ugen, KE ;
Chattergoon, M ;
Wang, B ;
Shah, A ;
Agadjanyan, M ;
Bagarazzi, ML ;
Javadian, A ;
Carrano, R ;
Coney, L ;
Williams, WV ;
Weiner, DB .
JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (06) :1501-1509
[4]   Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles [J].
Brand, D ;
Lemiale, F ;
Turbica, I ;
Buzelay, L ;
Brunet, S ;
Barin, F .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 (15) :1369-1377
[5]  
Costagliola S, 1998, J IMMUNOL, V160, P1458
[6]   NATIVE OLIGOMERIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEIN ELICITS DIVERSE MONOCLONAL-ANTIBODY REACTIVITIES [J].
EARL, PL ;
BRODER, CC ;
LONG, D ;
LEE, SA ;
PETERSON, J ;
CHAKRABARTI, S ;
DOMS, RW ;
MOSS, B .
JOURNAL OF VIROLOGY, 1994, 68 (05) :3015-3026
[7]   THE REV GENE-PRODUCT OF THE HUMAN IMMUNODEFICIENCY VIRUS AFFECTS ENVELOPE-SPECIFIC RNA LOCALIZATION [J].
EMERMAN, M ;
VAZEUX, R ;
PEDEN, K .
CELL, 1989, 57 (07) :1155-1165
[8]   A MOLECULAR CLONE OF HTLV-III WITH BIOLOGICAL-ACTIVITY [J].
FISHER, AG ;
COLLALTI, E ;
RATNER, L ;
GALLO, RC ;
WONGSTAAL, F .
NATURE, 1985, 316 (6025) :262-265
[9]   Comparisons of DNA-mediated immunization procedures directed against surface glycoproteins of human immunodeficiency virus type-1 and hepatitis B virus [J].
Fomsgaard, A ;
Nielsen, HV ;
Nielsen, C ;
Johansson, K ;
Machuca, R ;
Bruun, L ;
Hansen, J ;
Buus, S .
APMIS, 1998, 106 (06) :636-646
[10]   Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex [J].
Fouts, TR ;
Binley, JM ;
Trkola, A ;
Robinson, JE ;
Moore, JP .
JOURNAL OF VIROLOGY, 1997, 71 (04) :2779-2785